Naturo Agrotech Reports Zero Revenue in Q2 FY26 Amid Severe Compliance Failures
The company posted a net loss of ₹0.2 crore with no sales activity, while its auditor flagged major governance lapses and a potential delisting threat.
Naturo Agrotech India reported zero revenue and a net loss of ₹0.2 crore for Q2 FY26. Its statutory auditor issued a qualified opinion citing serious violations of the Companies Act, and the BSE has initiated compulsory delisting proceedings.
Naturo Agrotech India's Q2 FY26 results reveal a company in a state of operational and regulatory collapse. The firm, which purports to trade in agro-products and FMCG goods, reported zero revenue from operations for the quarter ended September 2025, alongside a net loss of ₹0.2 crore. This stark outcome is overshadowed by a qualified audit opinion flagging severe governance failures, casting doubt on the very substance of its business.
The numbers show a complete halt in trading activity. Revenue fell 100% both year-on-year and quarter-on-quarter, from ₹13.39 crore in Q2 FY25. The resulting net loss of ₹0.2 crore was driven entirely by operating expenses, as reported by ScanX.trade, with no sales to offset them. Over the trailing twelve months, the company managed revenue of ₹55.27 crore, but its net profit margin remains a thin 2.3%.
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ2 FY26 | Same quarter LYQ2 FY25 |
|---|---|---|
| Period | Quarter ended September 2025 | Quarter ended September 2024 |
| Revenue (₹ Cr) | 0.00YoY -100% | 13.39 |
| Profit (₹ Cr) | -0.20YoY -141% | 0.49 |
| Net Profit Margin (%) | – | 3.7 |
A business model in question
A report from ScanX.trade highlights a critical divergence between the company's stated operations and its balance sheet. While it claims to be in agro-trading, loans and advances of ₹552.2 crore constitute about 67% of total assets. This suggests capital is deployed in unsecured lending rather than core business, raising questions about commercial substance, especially with the auditor unable to confirm the recoverability of these sums.
The weight of regulatory failure
The statutory auditor, H. Rajen & Co., issued a qualified opinion citing multiple violations of the Companies Act. These include granting loans without shareholder approval and accepting borrowings from non-director parties. Furthermore, the BSE issued a show-cause notice for compulsory delisting in September 2026, as trading has been suspended since February 2026. The company faces over ₹27 lakh in outstanding fines, compounding its regulatory troubles.
An existential crossroads
The immediate future hinges on resolving these deep-seated governance and compliance issues. With trading suspended and a delisting threat looming, restoring investor confidence and operational credibility is a monumental task. The company's cash has dwindled to just ₹4.52 lakh, per ScanX.trade, against significant short-term obligations, indicating severe liquidity pressure.
Live Chart
· NATURO
(BSE)
ISIN: INE0JNB01012
Key Points
- Naturo Agrotech reported zero revenue and a net loss of ₹0.2 crore for Q2 FY26, indicating a complete halt in its core trading operations.
- The statutory auditor issued a qualified opinion, citing major violations of the Companies Act related to loans, borrowings, and inventory verification.
- The Bombay Stock Exchange has initiated compulsory delisting proceedings due to prolonged trading suspension and non-compliance.
- The company's balance sheet shows a heavy concentration in loans and advances (₹552.2 crore), raising doubts about its actual business model versus its stated one.
- Severe liquidity constraints exist, with minimal cash reserves against substantial short-term payables and regulatory fines.
Hexa Perspective
This quarter is less about earnings and more about corporate survival. The zero revenue figure confirms the trading business has stopped, while the qualified audit opinion and delisting notice point to a breakdown in basic governance. Investors are left weighing the recoverability of assets the auditor could not verify against a mountain of regulatory penalties.
The path forward requires not just restarting sales, but a complete overhaul of compliance, board oversight, and financial controls. Until the company can convincingly address the auditor's concerns and resolve its listing status, the financials are secondary to existential risk.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.